Search
Now showing items 41-50 of 106
Utilising novel therapies in the treatment of gastrointestinal cancers
(Institute of Cancer Research (University Of London), 2023-05-04)
Background:
Gastrointestinal (GI) malignancies are common and frequently lethal diseases. For most, treatment options revolve around chemotherapy where efficacy beyond second line is negligible, and toxicity is high. Novel ...
Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours.
(MDPI, 2023-08-13)
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. Surgical treatment is recommended for the majority of localised GIST, while systemic treatment is the cornerstone ...
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
(BMJ PUBLISHING GROUP, 2023-10-20)
The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new ...
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
(Elsevier BV, 2023-02-01)
BACKGROUND: This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR2 regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma ...
Machine learning for normal tissue complication probability prediction: Predictive power with versatility and easy implementation.
(ELSEVIER IRELAND LTD, 2023-03-01)
BACKGROUND AND PURPOSE: A popular Normal tissue Complication (NTCP) model deployed to predict radiotherapy (RT) toxicity is the Lyman-Burman Kutcher (LKB) model of tissue complication. Despite the LKB model's popularity, ...
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-10-20)
PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated ...
Automated detection and delineation of lymph nodes in haematoxylin & eosin stained digitised slides.
(Elsevier BV, 2023-01-01)
Treatment of patients with oesophageal and gastric cancer (OeGC) is guided by disease stage, patient performance status and preferences. Lymph node (LN) status is one of the strongest prognostic factors for OeGC patients. ...
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
(Elsevier BV, 2023-02-01)
BACKGROUND: Patients with borderline resectable pancreatic ductal adenocarcinoma have relatively low resection rates and poor survival despite the use of adjuvant chemotherapy. The aim of our study was to establish the ...
Reporting quality of CONSORT flow diagrams in published early phase dose-finding clinical trial reports: Improvement is needed.
(ELSEVIER SCIENCE INC, 2023-08-01)
BACKGROUND: This project aims to: (1) assess the completeness of information in flow diagrams of published early phase dose-finding (EPDF) trials based on CONSORT recommendations, and if additional features on dose ...
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
(American Society of Clinical Oncology (ASCO), 2023-02-13)
PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated ...